close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Novartis Pharma AG

News headline image
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
From Novartis Pharma AG
Via GlobeNewswire
News headline image
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
From Novartis Pharma AG
Via GlobeNewswire
News headline image
Novartis breaks ground on flagship manufacturing hub in North Carolina
From Novartis Pharma AG
Via GlobeNewswire
News headline image
Novartis announces plans to build flagship manufacturing hub in North Carolina
From Novartis Pharma AG
Via GlobeNewswire
News headline image
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
From Novartis Pharma AG
Via GlobeNewswire
News headline image
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
From Novartis Pharma AG
Via GlobeNewswire
News headline image
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
From Novartis Pharma AG
Via GlobeNewswire
News headline image
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
From Novartis Pharma AG
Via GlobeNewswire
News headline image
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
From Novartis Pharma AG
Via GlobeNewswire
News headline image
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
From Novartis Pharma AG
Via GlobeNewswire
News headline image
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
From Novartis Pharma AG
Via GlobeNewswire
News headline image
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
From Novartis Pharma AG
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today